Report from Brazil - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Report from Brazil
A look at why Brazil revised its GMP standards and how the changes will affect the local pharmaceutical industry.


Pharmaceutical Technology
Volume 34, Issue 9, pp. 18, 20

Local impact

"The main changes [to RDC 17] regard the need to 'Validate Computerized Systems' related with the process of production of pharmaceutical drugs," says Henrique Tada, technical regulatory manager in Brazil for the National Pharmaceutical Laboratories Association (Alanac) in Brazil.

According to Tada, the revised GMPs on computer validation and product revision are beneficial because they force pharmaceutical companies to comply with quality controls in order to supply the local market with high quality drugs. The changes will also help bring Brazil's pharmaceutical drug manufacture in line with regulatory standards of the most developed countries. (The revised GMP on validating computer systems used in the production of drugs will involve additional costs for companies and as a result, will not be enforceable for three years.)

"By complying with international practices, it is easier for domestically based pharmaceutical companies to [perform] export activities, especially national firms that have been growing steadily," adds Alanac's Tada.

Global harmonization

Other positive changes in the revised GMPs, according to specialists, are related to the global harmonization of procedures and the sharing of relevant information among international regulatory bodies. According to Anvisa, Brazil regularly collaborates with other regulatory and surveillance bodies with regard to information-sharing about inspections.

"Brazil, as a member of the Mercosur trade pact, participates actively in activities ... by sharing data and harmonizing procedures and rules," says Vogler. For example, Anvisa works regularly with the Pan American Network for Drug Regulatory Harmonization (PANDRH). The network was established in 1999 "to support processes on drug regulatory harmonization," according to the US Food and Drug Administration website. Participants in PANDRH include national authorities in the Americas, pharmaceutical interest groups, industry, and academia.

Although the Brazilian pharmaceutical industry does not participate in quality systems and analytical-testing activities as called for by the International Conference on Harmonization (ICH), notes Tada, Anvisa bases its technical guidelines on those of ICH.

Hellen Berger is a business writer based in São Paulo, Brazil.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here